Lü Chao, Shen Jing, Wu Nan, Zheng Qing-feng, Wang Jia, Yan Shi, Feng Yuan, Yang Yue
Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery, Peking University School of Clinical Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
Zhonghua Yi Xue Za Zhi. 2009 Sep 22;89(35):2481-5.
To establish a classification model and serum proteomic patterns in non-small cell lung cancer (NSCLC) patients with lymph node metastasis by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS).
The relative contents of serum proteins of 84 NSCLC patients with different N stages (35 N0 cases, 19 N1 and 30 N2 respectively) were detected by CM10 chip and SELDI-TOF-MS; two decision trees were generated to distinguish lymph nodes metastasis (N0 versus N1 + N2) and mediastinal lymph nodes metastasis (N0 + N1 versus N2) respectively.
The model in which 50 patients were randomly chosen differentiated patients with lymph nodes metastasis from N0 patients with a sensitivity of 96.3%(26/27) and a specificity of 95.7%(22/23) in the training set, a following blind test was taken. Subsequently, compared with 49 patients with lymph node metastasis (N1 + N2), 15 patients with total negative lymph nodes (including lobar, segmental and subsegmental nodes necessarily) were defined as "true" N0 and were chosen to form a better predictive model with a 77.6% (38/49) sensitivity and a 93.3% (14/15) specificity respectively. And 6682.0Da, together with other five proteins, had significant difference between two groups; the result of this model for distinguishing the mediastinal lymph nodes metastasis is more accurate than thoracic CT analyses by Alongi F and many other clinical centers. It had a sensitivity of 80.0% (24/30) and a specificity of 77.8% (42/54) respectively.
SELDI-TOF-MS showed a potential value for predicting lymph nodes metastasis in NSCLC patients. And further studies are required to confirm the models and identify the related proteins.
通过表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)建立非小细胞肺癌(NSCLC)伴淋巴结转移患者的分类模型和血清蛋白质组图谱。
采用CM10芯片和SELDI-TOF-MS检测84例不同N分期的NSCLC患者(35例N0期、19例N1期和30例N2期)血清蛋白的相对含量;分别生成两棵决策树以区分淋巴结转移(N0与N1+N2)和纵隔淋巴结转移(N0+N1与N2)。
在训练集中,随机选取50例患者建立的模型区分N0期患者与有淋巴结转移患者,灵敏度为96.3%(26/27),特异度为95.7%(22/23),随后进行了一次后续盲法测试。随后,将15例淋巴结完全阴性(包括叶、段和亚段淋巴结)的患者定义为“真正”的N0期,并与49例有淋巴结转移(N1+N2)的患者进行比较,以形成一个更好的预测模型,其灵敏度分别为77.6%(38/49),特异度为93.3%(14/15)。并且6682.0Da以及其他5种蛋白质在两组之间有显著差异;该模型区分纵隔淋巴结转移的结果比Alongi F等许多临床中心的胸部CT分析更准确。其灵敏度分别为80.0%(24/30),特异度为77.8%(42/54)。
SELDI-TOF-MS在预测NSCLC患者淋巴结转移方面显示出潜在价值。需要进一步研究以证实这些模型并鉴定相关蛋白质。